By Sherri Oslick --
Reckitt Benckiser LLC v. Dr. Reddys Laboratories, Inc. et al.
1:15-cv-04524; filed June 26, 2015 in the District Court of New Jersey
• Plaintiff: Reckitt Benckiser LLC
• Defendants: Reckitt Benckiser LLC; Dr. Reddys Laboratories, Ltd.
Infringement of U.S. Patent Nos. 6,372,252 ("Guaifenesin Sustained Release Formulation and Tablets," issued April 16, 2002), 6,955,821 ("Sustained Release Formulations of Guaifenesin and Additional Drug Ingredients," issued October 18, 2005), and 7,838,032 ("Sustained Release of Guaifenesin" issued November 23, 2010) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of plaintiff's Mucinex® D (guaifenesin/pseudoephedrine hydrochloride, respectively, used to treat chest congestion). View the complaint here.
Jazz Pharmaceuticals, Inc. v. Watson Laboratories, Inc.
2:15-cv-04532; filed June 26, 2015 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 8,859,619 ("Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy," issued October 14, 2014) and 8,952,062 (same title, issued February 10, 2015) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Jazz's Xyrem® (sodium oxybate, used to treat narcolepsy). View the complaint here.
Immunomedics, Inc. v. Board of Directors of Roger Williams Medical Center et al.
2:15-cv-04526; filed June 26, 2015 in the District Court of New Jersey
• Plaintiff: Immunomedics, Inc.
• Defendants: Board of Directors of Roger Williams Medical Center; M.D., PH.D. Richard P. Junghans; M.D. Steven C Katz; Office of the Board of Advisors of Tufts University School of Medicine; ABC Entities 1-10; John Does 1-10
Infringement of U.S. Patent Nos. 5,874,540 ("CDR-grafted Type III Anti-CEA Humanized Mouse Monoclonal Antibodies," issued February 23, 1999), 6,676,924 (same title, issued January 13, 2004), and 6,926,893 ("Multi-stage Cascade Boosting Vaccine," issued August 9, 2005) based on defendants' use, development and distribution of, and publication of information about antibodies or uses of antibodies allegedly covered by the '540 patent, and numerous claims sounding in tort. View the complaint here.